Mar 09,2024 TOP STORY

New real-world data shows MiniMed™ 780G system sustains strong global performance, exceeding international targets for diabetes management

Medtronic plc. shared new real-world data on the MiniMed™ 780G system at the ATTD conference in Florence, Italy, indicating its strong global performance in managing type 1 diabetes. The data showed that over 100,000 users achieved a Time in Range (TIR) of 78%, surpassing international targets. Additionally, the system helped users achieve Time in Tight Range (TITR) goals, with over 56% of users spending time in the 70-140 mg/dL glucose range. Early U.S. users of the system achieved over 80% TIR, surpassing international glycemic targets recommended by the ADA. The system also received high satisfaction ratings and improved quality of life benefits. These findings underscore the system's effectiveness in managing diabetes and advancing patient care.

CLINICAL STUDY

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Mar 12,2024 TOP STORY

New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications

DarioHealth presented two new clinical studies at the ATTD 2024 conference in Italy. The first study explored the impact of Dario's integrated solution for weight and diabetes management, with or without GLP-1 medications. It showed a 6.38% weight reduction among pre-diabetic users over a year, along with decreased blood glucose levels, particularly for those consistently engaged in meal tracking. The second study focused on improving flu vaccine awareness among Dario members with Type 1 or Type 2 diabetes. Results revealed that those receiving intervention messages showed higher self-reported vaccination rates compared to those who didn't. Members receiving more frequent messages reported even higher vaccination rates and greater awareness of flu risks.

CLINICAL STUDY

#coaching

#dtx

View Analyst & Ambassador Comments
Go to original news
Mar 08,2024

Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

Insulet Corporation presented positive results from its first randomized controlled trial (RCT) showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 Automated Insulin Delivery System. The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes in Florence, Italy. Insulet presented data for 194 adults who had used traditional (non-AID) insulin pump therapy (including 87% using the Omnipod or Omnipod DASH® Insulin Management System) for three months or longer and had a HbA1c between 7 and 11% (mean 8.5%). The participants had type 1 diabetes for at least one year and were enrolled at 14 institutions across the United States (61%) and France (39%). The participants were randomized into two groups and studied over the course of 13 weeks. The control group (n=62) continued to use their usual insulin pump with a Dexcom G6 CGM, while the intervention group (n=132) used Omnipod 5 with Dexcom G6. According to the results presented, the participants using Omnipod 5 showed a significantly greater TIR by 17.5% (43.8% in Control group versus 61.2% in Intervention group), or an additional 4.2 hours per day, and a greater reduction in HbA1c by 0.58% (1.24% with Omnipod 5 vs. 0.68% in the Control group). The final HbA1c was 7.25% in the Omnipod 5 group versus 7.84% in the Control group.

CLINICAL STUDY

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 08,2024 TOP STORY

Dexcom over-the-counter Stelo Glucose Biosensor wins FDA clearance

Dexcom has received FDA clearance for its over-the-counter continuous glucose monitoring (CGM) solution called Stelo, which offers round-the-clock glucose readings directly to smartphones. The wearable biosensor has a two-week battery life and detects normal as well as low or high glucose levels. It's tailored for adults managing diabetes with oral medications or needing insight into lifestyle impacts on blood sugar levels. While not indicated for problematic hypoglycemia, it aims to empower users with actionable insights. Stelo is set for online release in summer 2024.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 05,2024

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

Dexcom has unveiled new clinical evidence supporting CGM use for automated insulin delivery systems and demonstrated benefits for managing Type 2 diabetes at the 17th International Conference on Advanced Technologies and Treatments for Diabetes, held March 6-9, in Florence. They highlighted the positive outcomes of using their CGM in AID systems, including reduced severe hypoglycemia and diabetic ketoacidosis rates. The company also announced the launch of their G7 sensor in additional markets and the introduction of Dexcom ONE+. Dexcom also announced the phased launch of direct connectivity to Apple Watch for G7 iOS users, beginning with a phased launch available to all G7 iOS users in the second quarter of this year. The announcement means that Dexcom G7 will soon be the only CGM system that can connect directly to Apple Watch without always needing to carry an iPhone. Additionally, the company presented evidence linking CGM use to reduced mortality in people with Type 1 and Type 2 diabetes. They showcased data indicating improved HbA1c and glucose range for Type 2 diabetes patients using their CGM sensors, emphasizing the device's role in enhancing metabolic health.

PRODUCT

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Mar 15,2024 TOP STORY

Sugar.fit Receives $5M in Series A Funding

Diabetes-focused health tech startup Sugar.fit has received an additional $5 million in Series A funding from B Capital. This brings its total Series A funding, the first round of which occurred in November, to $16 million. In a statement, the company said it will use its additional funds to expand its offerings, increase its presence, and hasten R&D in diabetes management. Sugar.fit has also recently started operating diabetes clinics in Bangalore, which offer a range of services such as stress therapies, live fitness and yoga sessions, and VR chromotherapy.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Mar 14,2024 TOP STORY

Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq

Better Therapeutics announced that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was made at a special meeting of the board of directors on Wednesday evening, March 13, 2024. Further, as previously disclosed, the Company’s securities are subject to delisting from the Nasdaq Stock Market unless the Company presents a plan to regain compliance with Nasdaq’s continued listing standards before the Nasdaq hearings panel. The Company has voluntarily requested a delisting of its securities and expects its securities to be delisted in the near term.

View Analyst & Ambassador Comments
Go to original news
Mar 05,2024

Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

Better Therapeutics announced a major partnership with the American College of Lifestyle Medicine’s (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its FDA-authorized product, AspyreRx, available to support underserved patients through 1,400 Federally Qualified Health Center (FQHC) organizations. Starting in the second quarter of 2024, FQHC clinicians will have the opportunity to recommend AspyreRx to reinforce and advance healthful lifestyle behaviors, empowering patients to take greater control of their health destinies. The AspyreRx implementation is expected to run for two years. Better Therapeutics and ACLM are seeking additional partners and funding to support the implementation and maximize the initiative’s impact.

COLLABORATION PARTNERSHIP

#institution

#dtx

View Analyst & Ambassador Comments
Go to original news

The PECAN process in France

In our interview with Vincent Vercamer, the Project Director at Digital Health Delegation in the French Ministry of Health and Prevention, we unveiled details about the PECAN process in France, types of digital health solutions that can apply for reimbursement via PECAN, the key steps of the process, the similarities and differences between DIGA in Germany and PECAN, the pricing scheme of PECAN, success stories from the approved solutions and more.

Feb 27,2024

Omada Health to Showcase Innovations in Digital Health as Gold Level Sponsor at Virgin Pulse Thrive Summit 2024

Omada Health is thrilled to announce its participation as a Gold Level Sponsor at the highly anticipated Virgin Pulse Thrive Summit 2024, scheduled to take place in Atlanta, GA, from April 9-11. This dynamic event serves as a premier platform for industry leaders and innovators to connect, engage, and explore the latest advancements in digital health. Attendees can visit Omada's on-site booth located in the Partner Exhibit Hall to discover firsthand how Omada Health is revolutionizing digital health and well-being.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES